Mesdopetam

GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that it will showcase three abstracts at the AD/PD ™ 2026 - 20th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Copenhagen, Denmark, March 17-21, 2026. Abstract 701 - Results from REACT-PD - a randomised, placebo-controlled, multi-centre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson's disease will be presented by Fredrik Hansson, Director of Clinical Science and Biometrics & Susanna Waters, Director of Systems Pharmacology. Theme C, Poster Shift 02, March 19-21, Board 088. Abstract 2455 - Searching for novel CNS therapies in Parkinson's and Alzheimer's disease using Integrative Screening process (ISP): An AI/ML driven phenotypic drug discovery platform will be presented by Sebastian Oleszko, Research Scientist AI/Data Science. Theme C, Poster Shift 02, March 19-21, Board 157. Abstracts 2995 - Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort will be presented by Sebastian Oleszko, Research Scientist AI/Data Science and Susanna Waters, Director of Systems Pharmacology. Theme C, Poster Shift 02, March 19-21, Board 086. Abstract 701 Results from REACT-PD - a randomised, placebo-controlled, multi-centre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson's disease Recurrent falls are among the most problematic symptoms in PD, with no satisfactory treatment. Pirepemat enhances neurotransmission in the prefrontal cortex (PFC) by increasing synaptic availability of dopamine (DA) and norepinephrine (NA). This addresses impairment in mesocortical DA and NA, which is associated with executive dysfunction and falls in PD. REACT-PD, a Phase IIb study, evaluated the effect of 13 weeks of treatment with pirepemat on falls frequency in patients with PD. While topline results showed a markedly reduced fall rate across all treatment groups, but no statistically significant difference was found vs. placebo. Here we show results focusing on the effect of pirepemat in different plasma concentration intervals. A significant, U-shaped plasma concentration response pattern was observed, indicating that pirepemat, in an optimal plasma concentration range, could significantly and clinically meaningfully reduce falls in PD. The relative fall rate was reduced by 31% vs. placebo in the optimal plasma concentration range. The findings align with previous research of dopaminergic compounds acting in the PFC, suggesting that dosing of pirepemat should be individualized, based on plasma concentrations. In terms of the absolute number of falls, the effect at optimal concentrations corresponds to a reduction of 7 falls monthly vs. placebo. The reduction in falls observed in the optimal plasma concentration range was not associated with any change in motor symptoms. Collectively, the study results support further development of pirepemat. Authors: Joakim Tedroff, Fredrik Hansson, Erik Werner, Olivia Vu Van, Johanna Landström, Nicholas Waters, Clas Sonesson, Susanna Waters Theme C: α-SYNUCLEINOPATHIES / DRUG DEVELOPMENT, CLINICAL TRIALS / NEUROTRANSMITTER-BASED AGONISTS AND MODULATORS, GLP-1 RECEPTOR AGONISTS Abstract 2455 Searching for novel CNS therapies in Parkinson's and Alzheimer's disease using IntegrativeScreening process (ISP): An AI/ML driven phenotypic drug discovery platform Traditional, target-based drug discovery (DD) relies on a reductionist approach focused on optimizing an isolated target in in vitro systems, a strategy with known shortcomings such as uncertain translational capacity and inherent druggability issues. In contrast, ISP is a DD platform based on comparative in vivo phenotypic profiling, targeting neurotransmitter dysregulations in neurodegenerative and psychiatric disorders. ISP allows clustering of compounds in a multivariate space by their system response profile (response profiles on biomarkers including neurochemistry, gene expression, behavioural patterns). Here we present a significant advancement in the behavioural assessment tools, based on AI-driven identification of behavioural features captured by video recordings. This novel technology enhances overall phenotyping applied in ISP, further improves predictive accuracy, and reinforces the capability of ISP to identify druggable, safe, and innovative first-in-class candidate drugs. Authors: Susanna Waters, Peder. Svensson, Nicholas Waters, Erik. Werner, Daniel. Andersson, Fredrik. Wallner, Joakim Tedroff, Clas Sonesson, Sebastian Oleszko Theme C: α-SYNUCLEINOPATHIES / THERAPEUTIC TARGETS, MECHANISMS FOR TREATMENT / DOPAMINE, ACETYLCHOLINE, NEUROTRANSMITTERS, GLP-1 RECEPTOR Abstract 2995 Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort Levodopa induced dyskinesias (LIDs) represent a common, disabling complication of Parkinson's disease (PD), typically emerging after 5-10 years of levodopa-treatment. An extended-release (ER) formulation of amantadine, an NMDA-receptor antagonist with anti-cholinergic/ and dopamine-releasing properties, was approved for LIDs treatment in 2017. Here, we examined use patterns of amantadine in a large observational PD-cohort. Clinimetric, demographic, genotype and imaging data on 1340 subjects with PD were accessed November- 2025. Data were analysed with respect to overall correlation structure, factors discriminating subjects with/without amantadine, and factors discriminating subjects who discontinued amantadine. Amantadine was used by about 30% of subjects with dyskinesia, with roughly one-third eventually discontinuing as their disease progressed. Most patients received daily doses below 300 mg. Dyskinetic subjects on amantadine tended to have more severe PD symptoms across modalities, including overall severity, ADL-function, cognitive impairment, and motor symptoms including dyskinesias. In contrast, tremor was unrelated to amantadine use. Additionally, MDS-UPDRS part 3 scores, an objective motor assessment performed by clinicians, were generally lower among those receiving amantadine. Subjects on amantadine were more likely to have the "genetic" subtype, especially LRRK, while sporadic PD was linked to less amantadine use. Subjects who discontinued amantadine generally experienced more severe symptoms, although differences compared to those who continued were modest. Authors: Sebastian Oleszko, Joakim Tedroff, Susanna Waters, and Nicholas Waters Theme C: α-SYNUCLEINOPATHIES / DRUG DEVELOPMENT, CLINICAL TRIALS / NEUROTRANSMITTER-BASED AGONISTS AND MODULATORS, GLP-1 RECEPTOR AGONISTS For more details about the AD/PD ™ 2026 congress, please visit: For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se Nicholas Waters, EVP and Head of R&D Phone: +46 730 75 77 01 E-mail: nicholas.waters@irlab.se About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB to present clinical and preclinical data at the AD/PD ™ 2026 - 20th International Conference on Alzheimer’s & Parkinson’s Diseases SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, today announces that the first patient has been dosed in a Phase Ib study with IRL757 - a potential new treatment for Parkinson's disease-related apathy. This event triggers a USD 3 million milestone payment to IRLAB, payable in instalments in 2026. The study is fully funded by IRLAB's development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) - an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. "The progress in the clinical development of IRL757 as a potential new treatment for Parkinson's patients experiencing apathy triggers a USD 3 million milestone payment that will further strengthen IRLAB's financial position. The solid scientific and financial backing from our collaborator, MSRD, enables us to continue to develop this first-in-class drug candidate efficiently, with the aim to improve the quality of life for the vast number of persons who are currently lacking treatment options for this severely disabling condition," says Kristina Torfgård, CEO of IRLAB. The safety, tolerability and signal finding Phase Ib study, LIFT-PD, which will include 75 patients with Parkinson's disease who experience apathy, will be conducted at 16 study sites in Germany, Bulgaria, Poland, and Spain. Two previous Phase I studies, one in healthy young adults and one in healthy older adults aged 65 and above, both showed that IRL757 was well absorbed and provided good systemic exposure after 10 days of dosing. All participants completed both studies, and no serious adverse events were recorded. Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability affecting a substantial proportion of people living with Parkinson's disease and other neurodegenerative diseases. Currently, there are no drugs on the market to treat apathy. IRLAB and MSRD, a member of the global Otsuka family of pharmaceutical companies, formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment for apathy. IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's unique ability to counteract disturbances in central nervous system nerve signaling proposed to underly apathy in several neurological conditions. For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-26 11:58 CET. About IRL757 The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US). IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders. IRL75, currently in Phase Ib, is being developed for the treatment of apathy in neurodegenerative disorders. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire